Satralizumab (anti-IL-6RA), a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab (anti-IL-6RA) prevents dTAA formation and progression in rattus norvegicus. Satralizumab (anti-IL-6RA) can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg
Protein Function
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis.
Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.